GradedCalls Analysts
Loading the ledger…
Public news sources, graded against Yahoo Finance adjusted closes (adjusted for splits and dividends) through 16 Oct 2026. Not investment advice.
GradedCallsGradedCallsGradedCalls Analysts
Loading the ledger…
NYSE · Healthcare
AbbVie · Pharmaceuticals. Historical grades below use the calls in this ledger. The list is each analyst’s latest recommendation. The bar under it is the direction for grading, not a live street tally.
Direction for grading, from the latest active call of each analyst. Strong Buy, Buy, Overweight, and Outperform count as Buy. Hold, Neutral, and Equal-Weight count as Hold. Underperform, Underweight, and Sell count as Sell. The recommendation on the call — Target raise, Upgrade to Buy, Reiterate Overweight — is a separate label.
Overall factor · 60D
81/100Average of active call grades
GC score9/10GC 1→GC 10
GC 8–10. At or above 70 is STRONG on the GC Scale.
The overall factor is the average of the 0–100 grades on active calls at this horizon. A call superseded by a later note on the same ticker within 90 days stays visible and does not enter this average, the GC score, or the hit rate. How this is computed
Active graded
| Analyst | Firm | N | Hit | Overall factor/100 · GC 1–10 |
|---|---|---|---|---|
| Gavin Clark-Gartner | Evercore | 1 | 100% | 100/10010/10 |
| Mohit Bansal | Wells Fargo | 1 | 100% | 100/10010/10 |
| Steve Scala | TD Cowen | 1 | 100% | 96 |
These calls count toward the overall factor once the horizon has a price. An open window is listed and is not in the average yet.
| Date | Analyst | Recommendation | Directionfor grading | Target | Then | After | Return | Grade |
|---|---|---|---|---|---|---|---|---|
| Oct 9, 2026 | Michael YeeUBS | Target raise Desk rating stays Neutral | Hold | — | — | |||
| Oct 9, 2026 | Vamil DivanGuggenheim |
6
In this factor
Superseded
1
Visible, not scored
Hit rate
83%
Active calls only
If followed
+10.1%
Active directional calls
Active calls on ABBV were a full hit 83% of the time. Hit rate is not the rank.
| Alexandria Hammond | Wolfe | 1 | 100% | 93.2/10010/10 |
| Gary Nachman | Canaccord | 1 | 100% | 82.6/1009/10 |
| Navann Ty | BNP Paribas | 1 | 0% | 14.5/1002/10 |
Desk rating stays Buy
| Buy |
| — |
| — |
| Oct 8, 2026 | Carter GouldCantor | Target raise Desk rating stays Overweight | Buy | — | — |
| Oct 7, 2026 Supersedes Supersedes prior call on Aug 3, 2026 (within 90 days). Prior call | Terence FlynnMorgan Stanley | Target raise Desk rating stays Overweight | Buy | — | — |
| Sep 10, 2026 | Rajesh KumarHSBC | Target raise Desk rating stays Buy | Buy | — | — |
| Aug 20, 2026 | David AmsellemPiper | Target raise Desk rating stays Overweight | Buy | — | — |
| Aug 17, 2026 | Mohit BansalWells Fargo | Target raise Desk rating stays Overweight | Buy | $285.42 | +14.7% | Hit |
| Aug 13, 2026 | Alexandria HammondWolfe | Upgrade to Outperform Desk rating Peer Perform → Outperform | Buy | $279.40 | +12.1% | Hit |
| Aug 11, 2026 | Navann TyBNP Paribas | Target raise Desk rating stays Neutral | Hold | $274.78 | +10.5% | Miss |
| Aug 10, 2026 | Gavin Clark-GartnerEvercore | Target raise Desk rating stays Outperform | Buy | $274.78 | +11.5% | Hit |
| Aug 3, 2026 | Gary NachmanCanaccord | Target raise Desk rating stays Buy | Buy | $261.22 | +7.2% | Hit |
| Jul 31, 2026 | Steve ScalaTD Cowen | Reiterate Buy Desk rating stays Buy | Buy | $261.68 | +4.9% | Hit |